LLY

1,045.49

+3.03%↑

JNJ

231.51

+0.62%↑

ABBV

215.3

+0.85%↑

UNH

382.48

-0.15%↓

AZN

190.25

+1.48%↑

LLY

1,045.49

+3.03%↑

JNJ

231.51

+0.62%↑

ABBV

215.3

+0.85%↑

UNH

382.48

-0.15%↓

AZN

190.25

+1.48%↑

LLY

1,045.49

+3.03%↑

JNJ

231.51

+0.62%↑

ABBV

215.3

+0.85%↑

UNH

382.48

-0.15%↓

AZN

190.25

+1.48%↑

LLY

1,045.49

+3.03%↑

JNJ

231.51

+0.62%↑

ABBV

215.3

+0.85%↑

UNH

382.48

-0.15%↓

AZN

190.25

+1.48%↑

LLY

1,045.49

+3.03%↑

JNJ

231.51

+0.62%↑

ABBV

215.3

+0.85%↑

UNH

382.48

-0.15%↓

AZN

190.25

+1.48%↑

Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Abierto

SectorSanidad

31.66 -2.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

30.81

Máximo

32.69

Métricas clave
By Trading Economics
Ingresos	-200M -314M
Ventas	428K 2M
Margen de beneficios	-15,692.896
Empleados	750
EBITDA	-132M -290M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+26.52% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	4.9B 20B
Apertura anterior	33.76
Cierre anterior	31.66

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

13 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

11 / 11.18 Soporte y Resistencia

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 may 2026, 22:52 UTC

Principales Movimientos del Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 may 2026, 23:44 UTC

Ganancias

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 may 2026, 23:35 UTC

Charlas de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 may 2026, 23:30 UTC

Charlas de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 may 2026, 23:15 UTC

Charlas de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 may 2026, 23:14 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 may 2026, 23:02 UTC

Charlas de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 22:27 UTC

Charlas de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 may 2026, 22:14 UTC

Charlas de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 may 2026, 22:10 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 may 2026, 22:00 UTC

Ganancias

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 may 2026, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 may 2026, 21:27 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 may 2026, 21:20 UTC

Ganancias

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 may 2026, 21:19 UTC

Ganancias

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 may 2026, 21:18 UTC

Ganancias

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 may 2026, 21:17 UTC

Ganancias

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 may 2026, 21:16 UTC

Ganancias

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

26.52% repunte

Estimación a 12 Meses

Media 35.69 USD 26.52%

Máximo 41 USD

Mínimo 29.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

13 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.